DefinitionThis section has been translated automatically.
Prostaglandin derivative.
Half-lifeThis section has been translated automatically.
0,08–0,16 h
You might also be interested in
IndicationThis section has been translated automatically.
Peripheral arterial occlusive disease in stage III and IV, see also arterial occlusive disease, chronic.
Dosage and method of useThis section has been translated automatically.
Gradual dosage starting with 20 μg/day Alprostradil in 50-250 ml NaCl 0.9% slowly over at least 1 hour i.v., increase the dose to max. 60 μg/day.
Notice! In patients with heart failure, coronary heart disease, kidney dysfunction or peripheral oedema, the infusion volume should not exceed 50-100 ml/day!
Undesirable effectsThis section has been translated automatically.
Temperature rise, confusion, cerebral seizures, RR drop, tachycardia, arthralgia, flush, sweating, chills, fever, leukopenia, leukocytosis, hyperostosis of the long bones, acute pulmonary edema or heart failure. In the infused extremity: pain, erythema, redness.
InteractionsThis section has been translated automatically.
s. Table 1.
ContraindicationThis section has been translated automatically.
Pregnancy, lactation, heart failure, cardiac arrhythmia, CHD, 6 months after a heart attack, pulmonary edema, severe COPD, liver disease, acute bleeding.
PreparationsThis section has been translated automatically.
Prostavasin, Caverject, Muse, Minprog
TablesThis section has been translated automatically.
Main interactions of Alpostradil
Antihypertensives |
RR waste |
Anticoagulants |
Bleeding tendency ↑ |
Platelet aggregation inhibitor |
Bleeding tendency ↑ |
Vasodilators |
mutual effect ↑ |
Prof. Dr. med. Peter Altmeyer